bd 4

Mtb-cyt-bd oxidase-IN-4, an inhibitor of Mycobacterium tuberculosis cytochrome bd oxidase (Mtb cyt-bd oxidase), demonstrates potent activity with an IC50 value of 0.25 μM and inhibits the growth of Mycobacterium tuberculosis with a minimum inhibitory concentration (MIC) of 8 μM. This compound is utilized in tuberculosis research.

BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 µM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2. [BRD4-BD1-IN-2] is applicable for research in cardiovascular and cancer-related diseases.

dBRD4-BD1 is a selective BRD4 bromodomain inhibitor. dBRD4-BD1 can selectively degrade BRD4 (DC50 = 280 nM). Notably, dBRD4-BD1 upregulates BRD2/3, a result not observed with degraders using pan-BET ligands. Designing BRD4 selectivity up front enables analysis of BRD4 biology without wider BET-inhibition and simplifies designing BRD4-selective heterobifunctional molecules, such as degraders with new E3 recruiting ligands or for additional probes beyond degraders.

iBRD4-BD1 is a selective inhibitor of the BRD4 bromodomain, exhibiting inhibition activity with an IC50 value of 12 nM. It is utilized in the research of inflammation and oncology.

iBRD4-BD1 diTFA is a selective BRD4 bromodomain inhibitor with an IC50 value of 12 nM. It can be used for research in inflammation and oncology [1].

BRD4-BD1 2-IN-2 is a potent inhibitor of BRD4-BD2, effective on both BRD4 BD2 (IC50 < 0.5 nM) and BRD4 BD1 (IC50 < 300 nM).

BRD4-BD1-IN-1 (Compound 9a) is a BRD4-BD1 inhibitor with an IC50 of 38.20 μM.

BRD4-BD1 2-IN-1 is a highly effective inhibitor of BRD4, targeting the BRD4 BD-1 and BD-2 domains with IC50 values of <100 nM each (US20150148375A1, compound 5) [1].

ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with nanomolar binding affinities to the bromodomains (BDs) of BRD4, exhibiting IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.

BD 1008 Free Base is a selective sigma receptor antagonist, with a reported binding affinity of Kᵢ = 2 ± 1 nM for the sigma-1 receptor and 4 times selectivity over the sigma-2 receptor.

Mtb-cyt-bd oxidase-IN-6, a potent inhibitor of Mycobacterium tuberculosis (Mtb) cytochrome bd (cyt-bd) oxidase (MtbCyt-bd Oxidase), exhibits an inhibitory concentration (IC50) of 0.35 μM and effectively suppresses Mtb growth with a minimum inhibitory concentration (MIC) of 4 μM. This compound is utilized in tuberculosis research [1].